ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
Dow Jones
40,003.59
0.34%
Brent Oil
83.76
0.00%
Bitcoin
67,139.36
0.09%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. UroGen Pharma Ltd (URGN) Quote

UroGen Pharma Ltd

UroGen Pharma Ltd (URGN)

NASDAQ
13.22
0.01
(0.08%)
Closed May 18 4:00PM
Delayed by 15 minutes
13.22
0.00
(0.00%)
After Hours: 4:00PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
13.22
Bid
13.00
Ask
14.99
Volume
232,110
13.04 Day's Range 13.345
8.69 52 Week Range 24.13
Market Cap
452.8M
Previous Close
13.21
Open
13.22
Last Trade
99
@
13.5
Last Trade Time
Financial Volume
$ 3,052,840
VWAP
13.1526
Average Volume (3m)
332,508
Shares Outstanding
34,122,087
Dividend Yield
-
PE Ratio
-4.43
Earnings Per Share (EPS)
-3
Revenue
82.71M
Net Profit
-102.24M

About UroGen Pharma Ltd

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.urogen.com
Headquarters
Ra'anana, Center, Isr
Founded
1970
UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was $13.21. Over the last year, UroGen Pharma shares have traded in a share price range of $ 8.69 to $ 24.13.

UroGen Pharma currently has 34,122,087 shares outstanding. The market capitalization of UroGen Pharma is $452.80 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.43.

URGN Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 13 2024
Edgar (US Regulatory)

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024 ENVISION data expected to support completion of UGN-102...

May 13 2024
Business Wire

UroGen Pharma to Participate at Upcoming Investor Conferences

– Citizens JMP Life Sciences Conference – – H.C. Wainwright 2nd Annual BioConnect Conference – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

May 07 2024
Business Wire

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location RFS Was 100% in Patients who Received Maintenance...

May 05 2024
Business Wire

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and...

May 04 2024
Business Wire

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

May 04 2024
Business Wire

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

Conference Call and Webcast Scheduled for Monday, May 13, 2024, at 10:00AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions...

May 03 2024
Business Wire

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term...

April 17 2024
Business Wire

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten...

April 15 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.251.9275250578312.9714.0510.600144641913.2066604CS
4-0.84-5.9743954480814.0614.8910.600128426913.61684648CS
12-4.57-25.68858909517.7918.719410.600133250815.02816124CS
261.0258.4050840508412.19519.8710.600132356215.3228398CS
521.4712.510638297911.7524.138.6937850516.17865825CS
156-2.03-13.311475409815.2524.134.8520920613.99243866CS
260-25.34-65.715767634938.5639.884.8520000718.16720165CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.68M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.23M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.35M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.74B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.51M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.25M

Discussion

View Full Feed
Seminole Red Seminole Red 7 minutes ago
three most recent U.S. Open champions -- Wyndham Clark, Matt Fitzpatrick and Jon Rahm -- all fell on the wrong side of the 1-under cutline established Friday evening.
ProphetHero51 ProphetHero51 14 minutes ago
OK hopefully we have another green week starting on Monday.
appreciate your honesty and yes a little profit taking should be standard
I'll take that advice next time
NSAV
linkvest linkvest 15 minutes ago
His apartment is a tent on the street in Las Angeles
IGPK
Iron heart Iron heart 16 minutes ago
$$$ 👍
TONR
Seminole Red Seminole Red 18 minutes ago
The long day — there was a delay of 1 hour, 20 minutes because of the accident — finally ended in darkness with 18 players still to finish. They were to return Saturday morning. The cut, though not final, would be a PGA Championship record of at least 1-under par.
arachnodude arachnodude 19 minutes ago
Great article breaking down the RFI! Everything from potential award money to the background of why the need for it. Enjoy! Especially considering the author leads with a "spider silk" mention. 😁

https://breakingdefense.com/2023/03/pentagon-seeks-to-jumpstart-nascent-biomanufa
KBLB
helpx helpx 25 minutes ago
what will happen if no revenue in Q2?
UATG
Omar8 Omar8 33 minutes ago
AlwaysRed,


"They have to allow the price of silver to rise from time to time so their miners can remain profitable.......If they don't allow the prices to rise from time to time the miners can't exist."

"They will keep control of the price when it gets to the ch
SLV
ChrisMissing ChrisMissing 37 minutes ago
It looks like she was brought into the company by Terrie Kellmeyer who joined the company just 7 months ago as Sr. VP of Clinical Development and who she worked with at Acer. Great people hang with great people. Anavex continues to make some great hires.
AVXL
mrdecember123 mrdecember123 37 minutes ago
turtles are steady- one fine week for PAYS
PAYS
misterfishman misterfishman 40 minutes ago
The Europeans believe in this fuel cell engine enough to promise 100 million euro,s so that says a lot. We are going much higher here gl to all the patient peeps.
RONN
UPMI UPMI 40 minutes ago
That’s what I hoping as a newbie
CRKN
infamous infamous 46 minutes ago
Lol. It only took you from 10.00 to .23 to realize that...great job
VLCN
Scope08 Scope08 48 minutes ago
The fact that you, and Dice, and Dan, Nrdc, TP, GP, etc, etc, hide behind phrases like “critical thought” and “free speech” to spread your disinformation, is painfully obvious.

When you say it, you don’t actually mean it.

You chumps should really add a new catchphrase
LWLG
ChrisMissing ChrisMissing 48 minutes ago
Ok this to me is a great addition to the team.

http://linkedin.com/in/kim-tharaldsen

She looks to be filling a huge patient advocacy type need and by the looks of the people wishing her success she seems to be well liked by all.
AVXL
wickw50 wickw50 50 minutes ago
Stockman101010, I agree. The YouTube “gurus” are not credible.
AMC
jaymark jaymark 57 minutes ago
Fine, fine, fine..... but what's NEW other than more insider buying? What concrete developments have happened towards actual testing again? After that last test, where are the companies drooling over the chance to try it out? It should not take this long if there is much interest, or any genuine
QSEP
infamous infamous 58 minutes ago
Lol for MONTHS you've been saying NOT MUCH TIME TO ADD...NOT MUCH TIME TO ADD...NOT MUCH TIME TO ADD. we had nothing BUT time
EBET
Seminole Red Seminole Red 58 minutes ago
Andy Reed let the Chiefs organization know where he stands when he heard rumors that they were planning to fire Harrison Butker.
"You let the Kelce sideshow keep going even after he screamed at me on the field. Not this time. This is where I draw the line."
Reed said he's not concerned
Fronhilton Fronhilton 1 hour ago
L-serine https://www.youtube.com/watch?v=dS_cJferURA
AVXL
Edward Edward 1 hour ago
As a follow up.

The 9.7 million shares O/S is a lot for the reason below.

Don't forget that is after two major reverse splits and two smaller ones:

Capital Change=shs decreased by 1 for 500 split Pay date=05/02/2011.
Capital Change=shs decreased by
DTII

Your Recent History

NASDAQ
URGN
UroGen Pharma
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved